Huadong Medicine was selected as the 2022 Top 20 Competitive List of Chinese Pharmaceutical Listed Companies

time:2022-12-09 11:29:47source:chakarski.com author:Individual stock analysis
Huadong Medicine was selected as the 2022 Top 20 Competitive List of Chinese Pharmaceutical Listed Companies

Recently, under the guidance of the China Pharmaceutical Enterprise Management Association, the results of the selection of "Top 20 Competitive Chinese Pharmaceutical Listed Companies in 2022" jointly launched by E-pharmaceutical Manager Renrong Media and Jun Consulting were announced. Among them, Huadong Medicine Co., Ltd. stood out from many listed pharmaceutical companies and was selected into the top 20 list. The "Top 20 Competitiveness of China's Pharmaceutical Listed Companies" has been selected for 14 consecutive years. Through the five dimensions of "entrepreneurs, capital, industry, resources and management", enterprises are comprehensively assessed, and the comprehensive competitive strength can be explored from the strategic level. A Chinese listed pharmaceutical company that flexibly adapts to the industrial development cycle. Huadong Medicine Co., Ltd. (stock code: 000963), a top 20 Chinese pharmaceutical listed company in competitiveness in 2022, was founded in 1993, headquartered in Hangzhou, Zhejiang, and listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, dominated by the pharmaceutical industry, while expanding the pharmaceutical business, medical beauty industry and industrial microbiology business, and has developed into a large-scale comprehensive pharmaceutical integrating pharmaceutical R&D, production and distribution. Listed company. The company's pharmaceutical industry is deeply engaged in the research and development, production and sales of specialty, chronic disease drugs and special drugs. It has formed a complete pharmaceutical manufacturing and quality research system, and has formed a focus on chronic kidney disease, transplantation immunity, endocrine, digestive system and other fields. The core product pipeline of the company has a number of first-line clinical drugs with market advantages in China. At the same time, it focuses on innovative drugs and high-tech barriers in the three core therapeutic areas of tumor, endocrine and autoimmunity through independent development, external introduction, and project cooperation. Generic drug R&D layout. The company continues to carry out product international registration, international certification, consistency evaluation and other work, and continues to achieve results, has formed an international-oriented pharmaceutical industry system, and maintains R&D and product cooperation with many international innovative R&D companies. The company's pharmaceutical business has four major business sectors: Chinese and Western medicine, medical equipment, medicinal ginseng, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics featuring cold chain, pharmaceutical e-commerce, hospital value-added services, and special health. Industry, to further develop product agency and market expansion, the traditional Chinese medicine industry builds a whole industry chain from base planting to decoction piece processing, automated decoction, and functional products, providing customers with comprehensive solutions. The company's medical beauty business adheres to the strategy of "global operation layout, dual-cycle operation and development", with an international perspective, through forward-looking layout, has more than 30 products in the field of non-invasive + minimally invasive medical beauty, of which the products listed at home and abroad have reached There are more than 20 models, and more than 10 global innovative products are under research. The product portfolio covers non-surgical mainstream medical and aesthetic fields such as facial filling, facial cleansing, thread embedding, skin management, body shaping, hair removal, and private repair. It has formed a comprehensive Product clusters, product quantity and coverage areas are at the forefront of the industry. Sinclair, a wholly-owned subsidiary, is the company's global medical and aesthetic operation platform. It is headquartered in the United Kingdom and has production bases in the Netherlands, France, the United States, Switzerland and Bulgaria. Sinclair promotes and sells long-acting microspheres for injection, hyaluronic acid, and facial thread lifts and other products in the global market, and through its wholly-owned subsidiaries High Tech and Viora, develops and expands the energy source medical and aesthetic device business in the global market. The medical aesthetics sector also includes Xin Keli Aesthetics, a wholly-owned operation and sales subsidiary in the Chinese market, and R2 in the United States and Kylane in Switzerland, a technology research and development subsidiary with overseas shares. The company has been deeply engaged in the field of industrial microorganisms for more than 40 years. It has a solid industrial foundation and industrial transformation capabilities. It has successfully developed and manufactured a variety of microbial drugs, and has built a key technical system for the development and production of microbial products. The scale and technology of existing microbial fermentation products The level is at the leading level in the industry. It has three microbial R&D platforms in Sino-US Huadong, Huida Biology and Huiyi Biology, and five industrial bases in Hangzhou Xiangfuqiao, Qiantang New District, Jiangsu Jiuyang, Meiqi Health, and Meihua Hi-Tech. It has the largest scale in Zhejiang Province. Fermentation monomer workshop and industry-leading microbial drug production capacity, research and development capabilities cover all stages of microbial engineering technologies such as strain construction, metabolic regulation, separation and purification, enzyme catalysis, and synthetic modification, and have formed microbial project research and development, pilot scale, and commercial production. , engineering and utility systems guarantee a complete manufacturing system. At present, the company has accumulated more than 100 R&D projects in the field of industrial microorganisms.
Related content